Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis

Jian-Jun Yan a, Ying Lu b, Zheng-Ping Kuai c, Yong-Hong Yong d, *

a Division of Cardiology, Jiangning Hospital Affiliated Nanjing Medical University, Nanjing, China
b Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
c Department of Cardiology, Shanghai Meishan Hospital of Nanjing Medical University, Nanjing, China
d Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Received: August 3, 2016; Accepted: December 20, 2016

Abstract

Epidemiologic studies are inconsistent regarding the association between plasma copeptin level and heart failure (HF). The aim of this study was to perform a meta-analysis to determine whether high level of copeptin is correlated with incidence of HF and mortality in patients with HF. We searched PUBMED and EMBASE databases for studies conducted from 1966 through May 2016 to identify studies reporting hazard ratio (HR) estimates with 95% confidence intervals (CIs) for the association between plasma copeptin level and HF. A random-effects model was used to combine study-specific risk estimates. A total of 13 studies were included in the meta-analysis, with five studies on the incidence of HF and eight studies on the mortality of patients with HF. For incidence of HF, the summary HR indicated a borderline positive association of high plasma copeptin level with HF risk (HR, 1.60; 95% CI, 0.90–2.85). Furthermore, an increase of 1 standard deviation in log copeptin level was associated with a 17% increase in the risk of incident HF (HR, 1.17; 95% CI, 1.02–1.33). For all-cause mortality of patients with HF, we also found a significant association between elevated plasma copeptin level and increased mortality of HF (HR, 1.76; 95% CI, 1.33–2.33). Our dose–response analysis indicated that an increment in copeptin level of 1 pmol/l was associated with a 3% increase in all-cause mortality (HR, 1.03; 95% CI, 1.01–1.05). In conclusion, our results suggest that elevated plasma copeptin level is associated with an increased risk of HF and all-cause mortality in patients with HF.

Keywords: copeptin • heart failure • meta-analysis

Introduction

Arginine vasopressin (AVP), also known as antidiuretic hormone, is synthesized in the hypothalamus and secreted from the neurohypophysis in response to haemodynamic and osmotic changes [1]. Circulating level of AVP increases in various pathological conditions, especially in cardiovascular diseases [2]. However, circulating AVP is not a useful biomarker due to its short half-life and instability [3]. Copeptin, the C-terminal part of the pro-AVP, is secreted in parallel with AVP during processing of the precursor peptide. In contrast to AVP, copeptin is more stable and easier to measure with an automated immunoassay, making it potentially suitable as a surrogate biomarker for the unstable AVP [4].

Heart failure (HF) is a complex clinical syndrome characterized by increased activation of neuroendocrine axis [5]. To date, several studies have been conducted to investigate the association of plasma copeptin level with the risk and prognosis of HF [6]. However, the results of those observational studies remain inconsistent and have not yet been quantitatively summarized. Hence, we chose to conduct a meta-analysis to combine the results from the available prospective studies, to evaluate whether high plasma level of copeptin is associated with incidence of HF and adverse outcome in patients with HF.

Methods

Search strategy

We searched the PUBMED and EMBASE databases that included the years 1966 through May 2016. We used search terms ‘copeptin’ or ‘CT-proAVP’ or ‘CT-pro vasopressin’, combined with ‘heart failure’ or ‘cardiac failure’ or ‘AHF’ or ‘CHF’ in the full-text option. Titles and abstracts were screened to
exclude any obvious irrelevant studies. References of relevant studies and review articles were checked for additional studies. Two authors (J.J.Y and Y.L) conducted all searches independently.

Eligibility criteria

Studies were included if they met the following criteria: (i) prospective cohort studies of adult patients with longer than 1 year of follow-up and with a sample size of at least 100 patients; (ii) the outcome of interest was total HF incidence or mortality; (iii) hazard ratio (HR) estimates with corresponding 95% confidence intervals (CIs) were reported. If data were duplicated in more than one study, the most recent study was eligible for inclusion.

Data extraction

The following data were extracted by two investigators (J.J.Y and Y.L) independently using a predefined data extraction form the first author’s name; publication year; country; sex; age; number of participants; years of follow-up; outcome; the HR and corresponding 95% CI; and adjustment variables. For each study, we extracted the risk estimates that reflected the greatest degree of control for potential confounders. The results were compared, and any discrepancies were resolved by consensus.

Quality assessment

We chose to use the Newcastle–Ottawa Scale [7] for quality assessment because this tool appropriately evaluates the three most important domains of prospective cohort studies: selection of study participants (0–4 points), comparability of populations (0–2 points) and ascertainment of exposure to risk (0–3 points). Ratings for each item were added to provide a study quality score (maximal score = 9). Disagreements were resolved by discussion between the reviewers or in consultation with a third reviewer.

Statistical analysis

Analyses were performed using the Stata 12.0 software package (STATA Corp, College Station, TX, USA). The measure of effect of interest was HR with the corresponding 95% CI. Study-specific risk estimates were extracted from each article, and log risk estimates were weighted by the inverse of their variances to obtain a pooled risk estimate. Studies were combined using the DerSimonian and Laird random-effects model, which considers both within- and between-study variations [8]. The likelihood of heterogeneity of the studies was assessed using the Q and I² statistics. To avoid type II errors resulting from low power, we set the significance level at 0.10 instead of the more conventional level of 0.05 [9]. Subgroup analysis and sensitivity analysis were performed to analyse the potential sources of heterogeneity. For dose–response analysis, we used the generalized least-squares trend estimation (GLST) analysis based on the methods developed by Greenland and Longnecker [10, 11] to estimate study-specific slopes from the natural logarithm of the HR across categories of exposure. For each study, the median or mean level of copeptin for each category was assigned to each corresponding HR estimate. When the median or mean of per category was not provided in the article, we assigned to each class the dose corresponding to the mid-point of upper and lower boundaries. For the open-ended categories, we estimated the median value assuming a normal distribution density function. In studies that did not provide the number of cases and person-years in each exposure category, the variance-weighted least square (VWLS) regression model was used to estimate the slopes. Because these two methods require the risk estimates with their variance estimates for at least three quantitative exposure categories, the studies with only two categories were not included in this analysis. Then, we obtained the summary HR estimates by pooling the study-specific slopes, using the inverse of the corresponding variances as weights. Finally, publication bias was evaluated with Egger’s regression asymmetry test in which a P value less than 0.10 was considered statistically significant [12].

Results

Literature search and study characteristics

As shown in Figure 1, after review of 209 studies, our literature search identified 27 potentially relevant studies concerning the correlation of copeptin level with HF. Nine articles were excluded because of small sample size (<100 patients) [13–16] or short period of follow-up (<1 year) [17–21]. Two reports [22, 23] were excluded because of insufficient information. Another two studies [24, 25] were excluded because the end-point contained other cardiovascular events. One study [26] was excluded because it was updated by the same author [27] in 2010. Thus, our meta-analysis on the correlation of copeptin level with HF included 13 papers in total, with five studies [28–32] on the risk of HF and eight studies [27, 33–39] on the mortality of HF.

Table 1 summarizes the baseline patient characteristics and design of the five studies on the association of copeptin level with incident HF. A total of 15,631 participants and 629 cases were included. Two studies [29, 31] enrolled community-based populations, and the other three [28, 30, 32] studied patients with coronary artery disease (CAD). Two Studies were conducted in the United States [30, 32], and the remaining three were in Germany [28], Sweden [29] and the United Kingdom [31], respectively. The follow-up duration ranged from 1 to 14 years. All studies adjusted covariates which may affect the association of copeptin level with the risk of HF.

Table 2 summarizes the main features of the eight studies on the predictive value of copeptin level for all-cause mortality in patients with HF. A total of 2824 patients with chronic HF and 361 with acute HF were included. Three studies [27, 34, 35] were conducted in Austria, two studies [37, 38] were in Denmark, and the remaining three studies were in Norway [36], Italy [39] and Sweden [33], respectively. The follow-up duration ranged from 1 to 13 years. All studies, except Tentzeris et al.’s [35], adjusted the impact of confounders when assessing the correlation between copeptin level and prognosis of HF.

Plasma copeptin level and the risk of HF

Among the five studies, one [31] reported copeptin level as both categorical and continuous variables, one [32] reported as categorical
variable, and three [28–30] reported as continuous variables. When copeptin level was treated as categorical variable, the pooled HR based on two studies was 1.60 (95% CI, 0.90–2.85) (Fig. 2A). When copeptin level was treated as continuous variable, there was a dose–effect relationship between copeptin level and incidence of HF. For each 1 standard deviation (S.D.) increase in log copeptin level, the overall pooled HR for incident HF was 1.17 (95% CI, 1.02–1.33) (Fig. 2B). The Egger’s test for publication bias was not statistically significant ($P = 0.706$).

**Plasma copeptin level and all-cause mortality of HF**

The pooled HR from five studies [33–35, 37, 39] that treated copeptin level as categorical variables was 1.76 (95% CI, 1.33–2.33) for all-cause mortality, with mild heterogeneity ($I^2 = 54.8\%$, $P = 0.065$) (Fig. 3A). We used subgroup analyses and sensitivity analysis to identify sources of heterogeneity. Stratified analysis by geographical region, gender, age and sample size is shown in Table 3. When it was conducted by geographical region, the predictive effect of copeptin for the all-cause mortality of heart failure was more significant in Austrians with no significant heterogeneity (HR, 2.53; 95% CI, 1.67–3.85; $P$ for heterogeneity = 0.698; $I^2 = 0.0\%$) than in people from other countries. When it was conducted by sex, no significant heterogeneity was observed in males (HR, 1.62; 95% CI, 1.22–2.15; $P$ for heterogeneity = 0.317; $I^2 = 0.3\%)$. The result of sensitivity analysis in which one study was removed at a time showed that most of heterogeneity was accounted for the study by Balling *et al.* [37]. After excluding this single study, there was no study heterogeneity ($P = 0.343$, $I^2 = 9.9\%$), and the HR was 1.75 (95% CI, 1.37–
| Study (author, year, ref) | Area | Study design | Study population | Age (years) | Male (%) | Follow-up | Incident HF (n) | HF definition | Sample | Assay kit | Comparison copeptin level | HR (95% CI) | Adjustments | Quality score |
|--------------------------|------|--------------|------------------|-------------|----------|-----------|----------------|---------------|--------|----------|--------------------------|-------------|-------------|---------------|
| Kelly et al., 2008 [28]  | Germany | Cohort | 274 patients with acute MI | 63 (24–91) | 75 | Median = 381 days | 30 | Medical records of treatment for clinical HF with high-dose diuretics, isotope or intravenous nitrate | Plasma | BRAHMS | Continuous | 3.01 (1.10–8.21) | Age, creatinine, anterior, DM, hypertension, previous angina, LVEF, heart rate, Killip class | 4/2/2 |
| Smith et al., 2010 [29]  | Sweden | Cohort | 5187 residents | 57.6 ± 5.9 | 41 | Median = 13.8 years | 112 | ICD-8, 9, 10 | Plasma | BRAHMS | Per 1 S.D. log copeptin increase | 1.35 (1.03–1.77) | Age, gender, BP, antihypertensive treatment, BMI, LDL, HDL, smoking, DM, history of MI | 3/2/3 |
| Sabatine et al., 2012 [30] | United States of America | Cohort | 1868 patients with stable CAD | 64.1 ± 8.2 | 82.1 | Median = 4.8 years | 56 | Medical records of hospitalization with a primary cause of HF | Plasma | BRAHMS | Per 1 S.D. log copeptin increase | 1.08 (0.83–1.40) | Age, gender, weight, hypertension, DM, smoking, prior MI, prior PCI or CABG, systolic BP, eGFR, ratio of apoB/apoA, LVEF, aspirin use, beta-blocker use, lipid-lowering medication use | 4/1/2 |
| Wannamethee et al., 2014 [31] | United Kingdom | Cohort | 3870 men with no diagnosed HF | 68.61 ± 5.51 | 100 | Mean = 11 years | 254 | Twice medical records of HF symptoms, signs, investigations and treatment response | Plasma | BRAHMS | Per 1 S.D. log copeptin increase | 1.13 (0.97–1.42) | Age, smoking, physical activity, social class, alcohol intake, left ventricular hypertrophy, systolic BP, antihypertensive drugs, history of MI, angina, eGFR, FEV1, albumin, CRP | 4/2/3 |
| 1st quartile (≤ 2.46 pmol/l) | 1 |
| 2nd quartile (2.46–3.85 pmol/l) | 1.03 (0.68–1.55) |
| 3rd quartile (3.86–6.32 pmol/l) | 1.17 (0.79–1.73) |
| 4th quartile (≥ 6.32 pmol/l) | 1.18 (0.79–1.76) |
| O’Malley et al., 2014 [32] | United States of America | Cohort | 4432 patients with non-ST-elevated ACS | NM | 64.7 | 1 year | 177 | Medical records of HF symptoms, signs and treatment response | Plasma | BRAHMS | 4th quartile vs. 1st–3rd quartile | 2.12 (1.55–2.89) | Age, CAD, CAD risk factors, repeated rest pain, aspirin use, ST depression, history of chronic HF, creatinine clearance, BNP, cTnI | 3/0/2 |

ACS, acute coronary syndrome; BMI, body mass index; BNP, brain natriuretic protein; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; CRP, C-reactive protein; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in one-second; HDL, high-density lipoprotein; HF, heart failure; HR, hazard ratio; ICD, International Classification of Diseases; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; S.D., standard deviation.
| Study (author, year, ref) | Area          | Study design | Study population | Age (years) | Male (%) | Follow-up | Mortality (n) | Sample | Assay kit | Comparison copeptin level | HR (95% CI) | Adjustments | Quality score |
|---------------------------|---------------|--------------|------------------|-------------|----------|-----------|---------------|--------|-----------|--------------------------|-------------|-------------|---------------|
| Gegenhuber et al., 2007 [34] | Austria       | Cohort       | 137 patients with acute destabilized HF | 75 (65–80) for alive, 79 (72–83) for dead | 93.4 | 1 year | 41 death | Plasma | BRAHMS | 1st tertile (<15 pmol/l) | 1 | Unadjusted | 4/2/2 |
|                           |               |              |                  |             |          |           |               |        |           | 2nd tertile (15–45 pmol/l) | 2.22 (1.89–3.60) |            |               |
|                           |               |              |                  |             |          |           |               |        |           | 3rd tertile (>45 pmol/l)   | 5.38 (3.51–9.12) |            |               |
|                           |               |              |                  |             |          |           |               |        |           | 3rd tertile (>45 pmol/l) vs. 1st–2nd tertile (<45 pmol/l) | 2.26 (1.11–4.62) | Age, systolic BP, renal dysfunction, systolic dysfunction, NYHA Classes |               |
| Voors et al., 2009 [36]    | Norway        | Cohort       | 224 patients who developed acute HF after acute MI | 68/6 | 70.0 | 33 ± 7 months | 32 death | Plasma | BRAHMS | Per doubling | 1.83 (1.26–2.64) | Age, gender, renal function, previous MI, DM, treatment group | 4/2/2 |
| Masson et al., 2010 [39]   | Italy         | Cohort       | 1237 patients with chronic and stable HF | 67 ± 11 | 80.4 | Median = 3.9 (3.1–4.6) years | 332 death | Plasma | BRAHMS | 1st tertile (0.15–9.6 pmol/l) | 1 | Age, BMI, NYHA class, LVEF, ischaemic aetiology of HF, eGFR, heart rate, BP, diabetes, atrial fibrillation, COPD, prescription of beta-blockers, diuretics or digitalis, serum concentrations of bilirubin and fibrinogen | 4/1/2 |
|                           |               |              |                  |             |          |           |               |        |           | 2nd tertile (9.61–19.1 pmol/l) | 0.99 (0.66–1.31) |            |               |
|                           |               |              |                  |             |          |           |               |        |           | 3rd tertile (19.2–22.8 pmol/l) | 1.52 (1.12–2.07) |            |               |
| Neuhold et al., 2010 [27]  | Austria       | Cohort       | 181 patients with chronic systolic HF | 70 ± 12 | 65.0 | 2 years | 36 death | Plasma | BRAHMS | Continuous | 1.93 (1.23–3.01) | Age, gender, GFR, DM, ischaemic aetiology of HF | 4/2/2 |
| Tentzeris et al., 2011 [35] | Austria       | Cohort       | 172 consecutive patients with stable chronic HF | 65.87 ± 12.18 | 77 | Median = 1301 (707–1636) days | 36 death | Plasma | BRAHMS | >16.4 pmol/l | 2.69 (1.61–4.50) | Unadjusted | 4/0/2 |
| Alehagen et al., 2011 [33] | Sweden        | Cohort       | 470 elderly patients with symptoms of HF | 73 | 52.1 | Median = 4725 (242–5112) days | 226 all-cause death, including 146 cardiovascular event death | Plasma | BRAHMS | 1st quartile (<5.70 pmol/l) | 1 | Gender, DM, haemoglobin, GFR, NYHA class, ischaemic heart disease, hypertension, LVEF | 4/2/3 |
|                           |               |              |                  |             |          |           |               |        |           | 2nd quartile (5.70–9.95 pmol/l) | 1.04 (0.72–1.51) |            |               |
|                           |               |              |                  |             |          |           |               |        |           | 3rd quartile (9.96–18.0 pmol/l) | 1.33 (0.76–2.33) |            |               |
|                           |               |              |                  |             |          |           |               |        |           | 4th quartile (>18.0 pmol/l)   | 2.04 (1.38–3.02) |            |               |

Table 2 Characteristics of studies on plasma copeptin level and all-cause mortality of patients with HF
2.14). No potential publication bias was found (Egger’s test: \( P = 0.198 \)).

Our dose–response analysis indicated that an increase in copeptin level of 1 pmol/l was associated with a 3% increase in all-cause mortality (HR, 1.03; 95% CI, 1.01–1.05; Fig. 3B). There was a statistically significant heterogeneity among the study results (\( P = 0.000; I^2 = 86.5\% \)). The sensitivity analysis showed that most of heterogeneity was accounted for the study by Neuhold et al. [27]. After excluding this single study, there was no study heterogeneity (\( P = 0.761, I^2 = 0.0\% \)), and the HR for 1 pmol/l increase was 1.01 (95% CI, 1.00–1.02).

**Discussion**

The present meta-analysis evaluated the association of plasma copeptin level with the risk and mortality of HF based on published results from 13 cohort studies. Our results demonstrate an equivocal positive association between elevated plasma copeptin level and increased risk of suffering from HF and suggest that higher plasma level of copeptin was also a predictor of all-cause mortality in patients with HF.

Some studies [13, 16, 21, 23] which were not included in our meta-analysis also demonstrated significant positive correlation between elevated plasma copeptin level and incidence of HF. In a prospective single-hospital study based on patients with post-acute myocardial infarction (AMI), Khan et al. [23] found that plasma copeptin level was a significant independent predictor of HF. Another two studies conducted by Reinstadler et al. [13, 16] also showed that plasma copeptin level could be a predictor for the risk of adverse cardiac remodelling after AMI. In a study of patients presenting to the emergency department with dyspnoea as the chief complaint, plasma level of copeptin was significantly higher in patients with acute HF when compared to those with dyspnoea attributable to other causes [21]. In our meta-analysis, we observed a borderline positive association between elevated plasma copeptin level and the risk of HF (HR, 1.60; 95% CI, 0.90–2.85) when copeptin level was treated as categorical variable. Moreover, the pooled results when copeptin level was treated as continuous variable revealed that an increase of 1 S.D. increase in log copeptin level was related to a significant 17% increase in the risk of HF without indication of heterogeneity (\( P = 0.459, I^2 = 0.00\% \)). However, this may be an overestimate of the true magnitude of the association because of the limited number of studies. Two studies in which larger proportion of males (>80%) were recruited showed no significant positive relation [30, 31], whereas it has been demonstrated that copeptin levels were higher in the male volunteers compared with female [40]. Thus, the effects of gender differences on the association of copeptin with HF must be of concern and still warrant further investigation. Furthermore, in healthy individuals, the median value of plasma copeptin has been found to be 4.2 pmol/l (range, 1–13.8 pmol/l) [4]. Considering the observed plasma copeptin levels in patients with HF (10–50 pmol/l) [41] were much higher than 4.2 pmol/l, copeptin may also be served as a
novel biomarker for the diagnosis of HF. However, in two recent diagnostic studies based on older residents, although plasma copeptin levels were elevated in patients with acute HF, using copeptin did not significantly improve the diagnosis of HF [42, 43]. It seems that copeptin can provide important prognostic information for the development of HF in patients with CAD, especially in patients with previous MI; however, its diagnostic role in HF has not been convinced. Studies with larger sample sizes are needed to validate the value of copeptin assessment alone or combined with other biomarkers, such as brain natriuretic protein (BNP), for rapid rule out of HF.

Another important finding of our meta-analysis is that elevated plasma copeptin level was associated with significantly increased all-cause mortality in patients with HF. In 2006, copeptin was first demonstrated to be an excellent predictor of outcome in advanced HF patients by Stoiser et al. [22]. With a mean follow-up period of 15.8 months, copeptin was found to be superior to BNP in predicting mortality and combined end-point of mortality and rehospitalization due to HF. Neuhold et al. [26] also found that copeptin was the most potent single predictor of mortality in HF patients with New York Heart Association (NYHA) functional class II and III. In NYHA functional class IV, although sodium level was the best predictor of mortality, copeptin could still add additional independent information in contrast to BNP.

Similarly, for the prediction of 90-day mortality in patients with acute HF, copeptin was also an independent predictor of mortality with additive prognostic value [17, 20]. The data of our meta-analysis are consistent with the results of above studies. In subgroup analyses by geographical region, gender, age and sample size, we found that the positive correlation between them was generally unchanged. Our finding was further strengthened by the absence of publication bias and the result of dose–response analysis, which indicates that an increase of 1 pmol/l of copeptin level was related to a 3% increase in all-cause mortality of patients with HF. It appears that copeptin could be served as a novel superior predictor of outcome in HF besides BNP. However, in the study of Balling et al. [37], although copeptin was a significant predictor of hospitalization or death (HR, 1.4; 95% CI, 1.1–1.9), it did not predict mortality alone independently from NT-proBNP. Indeed, on the basis of our sensitivity analysis, after exclusion of this study, we found a more significantly positive association (HR, 1.94; 95% CI, 1.50–2.51) with more homogeneous ($P = 0.248; I^2 = 27.4\%$). The discrepancy may be explained in part by the more serious status of patients in this study, which contained a large proportion of patients with NYHA class III/IV [37]. Therefore, larger studies are needed to further investigate the different predictive abilities of copeptin and NT-proBNP for patients with HF, especially for patients in different...
stages. Considering HF is a dynamic syndrome characterized by dramatically increased neurohormonal activation, it should be better to use the combination of copeptin with other biomarkers to improve the predictive effect of adverse outcome in patients with HF.

The mechanisms by which copeptin is elevated in patients with HF and predicts worse prognosis remain unclear. As AVP secretion is partly stimulated in response to increased osmolality, it seems unexpected that AVP is increased in patients with HF, which is characterized with low osmolality. The potential explanation may attribute to hyponatraemia and decreased cardiac output, which can also activate the secretion of AVP through baroreceptors [44]. This elevation might be beneficial to maintain blood pressure in the short term, but long-term excessive secretion of AVP can lead to adverse cardiac remodelling process via vasopressin 1a receptors [45]. However, AVP has a short half-life of 24 minutes [3]. Thus, copeptin might better reflect stable levels of AVP related to the severity of HF.

Several limitations of our study should be considered. First, the articles included were all published in English; limited resources prevented us from including articles published in other languages. Second, the number of included studies is relatively small. Although the Egger’s test was not statistically significant, publication bias may still exist. Third, we cannot resolve uncontrolled confounders as a potential explanation for the observed association, because a meta-analysis cannot exclude residual or unknown confounders that could be inherent in those original studies. Fourth, all studies included were conducted in Europe.

**Fig. 3 (A)** Forest plot demonstrating the association between plasma copeptin level and all-cause mortality in patients with heart failure (HF) (categorical variable). **(B)** Forest plot demonstrating the dose–effect relationship between plasma copeptin level and all-cause mortality in patients with HF. CI, confidence interval; HR, hazard ratio.

| Study ID          | HR (95% CI)     | Weight (%) |
|-------------------|-----------------|------------|
| Gegenhuber A et al. (2007) | 2.26 (1.11, 4.62) | 11.03      |
| Masson S et al. (2010)   | 1.52 (1.12, 2.07) | 26.19      |
| Tzenteris I et al. (2011) | 2.69 (1.61, 4.50) | 16.75      |
| Atehagen U et al. (2011) | 2.04 (1.38, 3.02) | 21.90      |
| Baling L et al. (2012)    | 1.20 (0.90, 1.80) | 24.12      |
| **Overall** (I² = 54.8%, P = 0.065) | 1.76 (1.33, 2.33) | 100.00     |

| Study ID          | HR (95% CI)     | Weight (%) |
|-------------------|-----------------|------------|
| Gegenhuber A et al. (2007) | 1.06 (1.04, 1.08) | 22.37      |
| Masson S et al. (2010)   | 1.01 (1.00, 1.02) | 26.46      |
| Neuhold S et al. (2010)  | 1.93 (1.23, 3.01) | 0.19       |
| Atehagen U et al. (2011) | 1.03 (1.02, 1.04) | 26.53      |
| Bosselmann H et al. (2013)| 1.02 (1.01, 1.04) | 24.45      |
| **Overall** (I² = 86.5%, P = 0.000) | 1.03 (1.01, 1.05) | 100.00     |
and the United States; therefore, the results should be extrapo-
lated to all populations with caution.

Conclusions

In conclusion, results from the present study suggest that elevated plasma copeptin level is associated with an increased risk of HF and all-cause mortality in patients with HF. Copeptin may serve as a practical guide for the prevention and treatment of HF.

Funding source

This work was supported by grants from the Six Talent Peaks Project in Jiangsu Province (No. WSN-037) to Y.H.Y.

Conflict of interest

The authors declare that they have no competing interest.

References

1. Singh Ranger G. The physiology and emerging roles of antidiuretic hormone. *Int J Clin Pract*. 2002; 56: 777–82.
2. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. *Am J Cardiol*. 2005; 95: 88–138.
3. Robertson GL, Mahr EA, Athar S, et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. *J Clin Invest*. 1973; 52: 2340–52.
4. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin Chem*. 2006; 52: 112–9.
5. Fiore G, Suppress P, Triggiani V, et al. Neuroimmune activation in chronic heart failure. *Endocr Metab Immune Disord Drug Targets*. 2013; 13: 68–75.
6. Giannopoulos G, Deftereos S, Panagopoulou V, et al. Copeptin as a biomarker in cardiac disease. *Curr Top Med Chem*. 2013; 13: 231–40.
7. Wells GA, Shea A, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7: 177–88.
9. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. *Psychol Methods*. 2001; 6: 203–17.
10. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol*. 1992; 135: 1301–9.
11. Orsini N, Bellocchio R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. *Stata J*. 2006; 6: 40–57.

Table 3 Subgroup analyses of the association between plasma copeptin level and all-cause mortality in patients with HF

| Subgroup               | Number | HR (95% CI)       | Heterogeneity test | Q    | P    | I² (%) |
|------------------------|--------|-------------------|--------------------|------|------|--------|
| Geographical region    |        |                   |                    |      |      |        |
| Austria                | 2      | 2.53 (1.67–3.85)  | 0.15               | 0.698| 0.0  |
| Other countries        | 3      | 1.53 (1.16–2.03)  | 3.96               | 0.138| 49.4 |
| Males                  |        |                   |                    |      |      |        |
| >80%                   | 2      | 1.62 (1.22–2.15)  | 1.00               | 0.317| 0.3  |
| <80%                   | 3      | 1.82 (1.14–2.92)  | 7.78               | 0.020| 74.3 |
| Age                    |        |                   |                    |      |      |        |
| <70                    | 2      | 1.95 (1.12–3.39)  | 3.49               | 0.062| 71.4 |
| ≥70                    | 3      | 1.68 (1.11–2.55)  | 2.48               | 0.081| 60.2 |
| Sample size            |        |                   |                    |      |      |        |
| <400                   | 3      | 1.87 (1.06–3.29)  | 7.46               | 0.024| 73.2 |
| >400                   | 2      | 1.72 (1.29–2.28)  | 1.34               | 0.247| 25.5 |

CI, confidence interval; HF, heart failure; HR, hazard ratio.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–34.
13. Reinstadler SJ, Klug G, Feistritz HJ, et al. Long-term predictive value of copeptin after acute myocardial infarction: a cardiac magnetic resonance study. Int J Cardiol. 2014; 172: e359–60.
14. Melekovsky V, Kotrc M, Polak J, et al. Availability of energetic substrates and exercise performance in heart failure with or without diabetes. Eur J Heart Fail. 2012; 14: 754–63.
15. Benes J, Kotrc M, Borlauge BA, et al. Resting heart rate and heart rate reserve in advanced heart failure have distinct pathophysiologic correlates and prognostic impact: a prospective pilot study. JACC Heart Fail. 2013; 1: 259–66.
16. Reinstadler SJ, Klug G, Feistritz HJ, et al. Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction. Heart. 2013; 99: 1525–9.
17. Vetron F, Santarelli S, Russo V, et al. Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea. Clin Chem Lab Med. 2014; 52: 1457–64.
18. Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011; 18: 947–58.
19. Potocki M, Breidhardt T, Mueller A, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care. 2010; 14: R213.
20. Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011; 4: 613–20.
21. Dieplinger B, Gegenhuber A, Haltmayer M, et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009; 95: 1508–13.
22. Stoiser B, Mortl D, Hulsman M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006; 36: 771–8.
23. Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007; 115: 2103–10.
24. Miller WL, Grill DE, Struck J, et al. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am J Cardiol. 2013; 111: 880–5.
25. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2012; 98: 369–94.
26. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52: 266–72.
27. Neuhold S, Huelsmann M, Strunk G, et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem. 2010; 56: 121–6.
28. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008; 14: 739–45.
29. Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 56: 1712–9.
30. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012; 125: 233–40.
31. Wannamethee SG, Welch P, Whincup PH, et al. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study. Eur J Heart Fail. 2014; 16: 25–32.
32. O’Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36). J Am Coll Cardiol. 2014; 63: 1644–53.
33. Alehagen U, Dahlstrom U, Rehfell JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011; 305: 2088–95.
34. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Cardiac Fail. 2007; 13: 42–9.
35. Tzentzis I, Jarai R, Farhan S, et al. Comparative role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2013; 15: 726–33.
36. Voors AA, van Heeplingen S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009; 30: 1187–94.
37. Balling L, Kistorp C, Schou M, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Cardiac Fail. 2012; 18: 351–8.
38. Bosselmann H, Egstrup M, Rossing K, et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol. 2013; 170: 202–7.
39. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasostic peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010; 12: 388–47.
40. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009; 116: 257–63.
41. Bolignano D, Cabassi A, Fiacchadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014; 52: 1447–56.
42. Mason JM, Hancock HC, Close H, et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS ONE. 2013; 8: e53560.
43. **Bahmann P, Bahmann A, Hofner B, et al.** Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department. *Eur Heart J Acute Cardiovasc Care.* 2015; 4: 137–47.

44. **Oghlakian G, Klapholz M.** Vasopressin and vasopressin receptor antagonists in heart failure. *Cardiol Rev.* 2009; 17: 10–5.

45. **Fan YH, Zhao LY, Zheng QS, et al.** Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. *Life Sci.* 2007; 81: 327–35.